SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2016. Vol. 61. No. 2. P. 58-64

RADIATION THERAPY

A.O. Rasulov, D.V. Kuzmichev, V.A. Aliev, Z.Z. Mamedli, S.S. Gordeyev, V.M. Kulushev, A.V. Polinovskiy, I.Sh. Tataev, J.M. Madyarov, A.V. Nazarenko, S.I. Tkachev, V.V. Glebovskaya, N.A. Kozlov

Neoadjuvant Chemoradiotherapy with Consolidation Chemotherapy in Complex Treatment of Locally Advanced Rectal Cancer

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: To investigate preliminary results of neoadjuvant chemoradiotherapy followed by neoadjuvant chemotherapy in locallyadvanced rectal cancer patients.

Material and methods: Patients aged >18 with histologycally verified MRI-staged low and medium T3 (CRM+)–4N0–2M0 rectal cancer were included. In group A (21 patients) received a preoperative chemoradiation with GENUS 4 Gy 3 times a week, with regional lymph nodes of 32 Gy to the tumor of the rectum 40 Gy with capecitabine 850 mg/m2 bid per os followed by 2 cycles of XELOX. In group B (20 patients) received the same treatment without consolidating chemotherapy. Toxicity, tumor regression, downstaging and postoperative complications were analyzed.

Results: 40 patients completed treatment according to the protocol. The second XELOX chemotherapy was amended in 1 patient in group A due to cardiac toxicity. Grade 3 toxic events were observed in 2 (9.5 %) patients in group A and in 3 (15 %) patients in group B. No grade 4 toxic events were observed. The median follow-up was 10.8 months. No patients experienced disease progression during this period. Postoperative complications were observed in 17.7 % and in 15 % of the patients respectively. Complete response was observed in 9 (42.9 %) patients in group A. Among those, 4 were referred to watchful waiting and 5 were diagnosed with pathological complete response after surgery. In group B complete response was observed in 3 (15 %) patients.

Conclusions: Combined treatment with consolidating chemotherapy represents a promising strategy for rectal.

Key words: locally advanced rectal cancer, the complex treatment of rectal cancer, chemotherapy is consolidating, medical pathomorphosis

REFERENCES

  1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013. Vol. 49. No. 6. P. 1374-1403.
  2. Stewart B.W., Wild C.P. IARC Nonserial Publication. 2014. 630 p.
  3. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010. Т. 23. № 3.
  4. The Beyond TME Collaborative. Brit. J. Surg. 2013. Vol. 100. No. 8. P. 1009-1014.
  5. Bouzourene H., Bosman F.T., Seelentag W. et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002. Vol. 94. No. 4. P. 1121-1130.
  6. Braendengen M. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J. Clin. 2008. Vol. 26. No. 22. P. 3687-3694.
  7. Bulow S., Jensen L.H., Altaf R. et al. National cohort study of long-course preoperative radiotherapy in primary fixed rectal cancer in Denmark. Colorectal Dis. 2010. P. 12.
  8. Eich H.T., Stepien A., Zimmermann C. et al. Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther Onkol. Vol. 187. P. 225-230.
  9. Kapiteijn E., Marijnen C.A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 2001. Vol. 345. P. 638-646.
  10. Sanghera P., Wong D.W., McConkey C.C. et al. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin. (R. Coll. Radiol.) 2008. Vol. 20. No. 2. P. 176-183.
  11. Vestermark L.W., Jensen H.A. et al. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with nonresectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol. 2012. Vol. 51. No. 3. P. 311-317.
  12. Bosset J.F., Collette L., Calais G. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006. Vol. 355. P. 1114-1123.
  13. Guckenberger M., Saur G., Wehner D. et al. Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. Strahlenther. 2012. Bd. 188. P. 551-557.
  14. Kim N.K., Baik S.H., Seong J.S. et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg. 2006. Vol. 244. No. 6. P. 1024-1030.
  15. Peeters K.C., Marijnen C.A., Nagtegaal I.D. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. 2007. Vol. 246. P. 693-701.
  16. Sauer R. Becker H. Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med., 2004. Vol. 351. P. 1731-1740.
  17. Videtic G.M., Fisher B.J., Perera F.E. et al. Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int. J. Radiat. Biol. Phys. 1998. Vol. 42. No. 2. P. 319-324.
  18. An X., Lin X., Wang F. et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur. J Cancer. 2013. Vol. 49. No. 4. P. 843-851.
  19. Bria E.G.R., Raftopoulos H. et al. Comparing two methods of meta-analysis in clinical research individual patient data-based (IPD) and literature-based abstracted data (AD) methods: analyzing five oncology issues involving more than 10.000 patients in randomized clinical trials (RCTs). J. Clin. Oncol. 2007. Vol. 25. Abstr. 6512.
  20. Gollins S.W., Myint S., Susnerwala S. et al. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). Brit. J. Cancer. 2009. Vol. 101. No. 6. P. 924-34.
  21. Iles S., Gollins S., Susnerwala S. et al. Irinotecan+5- fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study. Brit. J. Cancer. 2008. Vol. 98. No. 7. P. 1210-1216.
  22. Levine E.L., Gollins S., Susnerwala S. et al. Phase II study of radiotherapy plus concurrent irinotecan (CPT-11) and infusional 5-fluorouracil (5FU) in the treatment of T3-T4 locally advanced inoperable rectalcancer. J. Clin. 2004. Vol. 22. P. 3612.
  23. Rodel C., Liersch T., Becker H. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012. Vol. 13. P. 679-687.
  24. Roh M.S., Yothers G.A., O’Connell M.J. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum. J. Clin. 2011. Vol. 2. No. 9. Abstr. 3503.
  25. Al-Gizawy S.M., Essa H.H., Ahmed B.M. Chemotherapy alone for patients with stage II/III rectal cancer undergoing radical surgery. Oncologist. 2015. Vol. 20. No. 7. P. 752-757.
  26. Arimoto A., Uehara K., Tsuzuki T. et al. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int. J. Clin. 2015. Vol. 20. No. 5. P. 935-942.
  27. A., Weiser M. et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J. Clin. Oncol., 2010. Vol. 28. No. 5. Abstr. 3649.
  28. Ishii Y., Hasegawa H. et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan. 5-fluorouracil. and leucovorin in patients with locally advanced rectal cancer. Eur. J. Surg. 2010. Vol. 36. No. 11. P. 1061-1065.
  29. Schrag D., Weiser M.R., Goodman K.A. et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J. Clin. 2014. Vol. 32. No. 6. P. 513-518.
  30. Schrag D., Weiser M. et al. Neoadjuvant FOLFOX-bev. without radiation. for locally advanced rectal cancer. J. Clin. Oncol. 2010. Vol. 28. P. 263. Abstr. 3511.
  31. Matsumoto T., Hasegawa S., Zaima M. et al. Outcomes of neoadjuvant chemotherapy without radiation for rectal cancer. United Eur. J. 2014. Vol. 2. No. 1. A132-A605.
  32. Jalil O., Claydon L., Arulampalam T. et al. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer. Gastrointest. 2014.
  33. Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 1997. Vol. 12. P. 19-23
  34. Chua Y.J., Barbachano Y., Cunningham D. et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010. Vol. 11. P. 241-248.
  35. Gao Y.H., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther. 2014. Vol. 190. P. 158-164.
  36. Garcia-Aguilar J., Smith D.D., Avila K. et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann. 2011. Vol. 254. P. 97-102.
  37. Habr-Gama A., Perez R.O., Sabbaga J. et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis. Rectum. 2009. Vol. 52. P. 1927-1934.
  38. Zampino M.G., Magni E., Leonardi M.C. et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int. J. Radiat. Biol. Phys. 2009. Vol. 75. P. 421-427.
  39. Borg C., André T., Mantion G. et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized. Noncomparative phase II study. Ann. Oncol. 2014. Vol. 25. No. 11. P. 2205-2210.
  40. Kennecke H., Berry S., Wong R. et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur. J. Cancer. 2012. Vol. 48. P. 37-45.
  41. Nogue M., Salud A., Vicente P. et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011. Vol. 16. P. 614-620.
  42. Landry J.C., Feng Y., Prabhu R.S. et al. Phase II Trial of Preoperative Radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN cancer research group E3204. Oncologist. 2015. Vol. 29. P. 106.
  43. Wang C.C., Liang J.T., Tsai C.L. et al. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World J. Surg. 2014. Vol. 12. P. 329.
  44. Dellas K., Buller J., Görtz G.J. et al. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgeryassociated spectrum of complications. Ann. Oncol. 2014. Vol. 21. No. 4. P. 1352-1360.
  45. Dellas K. Höhler T. Reese T. et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiation Oncology. 15 April 2013. Vol. 8. Issue 1, 90.
  46. Fernandez-Martos C., Pericay C., Aparicio J. et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imagingdefined, locally advanced rectal cancer: grupo cancer de recto 3 study. J. Clin. Oncol. 2010. Vol. 28. P. 859-865.

For citation: Rasulov AO, Kuzmichev DV, Aliev VA, Mamedli ZZ, Gordeyev SS, Kulushev VM, Polinovskiy AV, Tataev ISh, Madyarov JM, Nazarenko AV, Tkachev SI, Glebovskaya VV, Kozlov NA. Neoadjuvant Chemoradiotherapy with Consolidation Chemotherapy in Complex Treatment of Locally Advanced Rectal Cancer. Medical Radiology and Radiation Safety. 2016;61(2):58-64. Russian.

PDF (RUS) Полная версия статьи

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2930938
Today
Yesterday
This week
Last week
This month
Last month
For all time
468
3096
8175
33458
29233
113593
2930938
Forecast today
2880

Your IP:216.73.216.244
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх